Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.
You may also be interested in...
MiddleBrook Aims To Address $600 Million Strep Market With Moxatag
Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.
MiddleBrook Aims To Address $600 Million Strep Market With Moxatag
Company plans to launch the first once-daily amoxicillin formulation for patients over 12 in the fall.
Advancis Gets Second Chance On Pulsatile Amoxicillin NDA
Firm plans to resubmit application with additional information in March.